CPHI Barcelona 2023: SINOVAC Showcases Comprehensive Product Portfolio
Pioneering Antibody Products and WHO Approved Vaccines Will Advance Prevention and Treatment of Infectious Diseases
October 19, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, will showcase groundbreaking products and an extensive portfolio targeting various infectious diseases at CPHI Barcelona 2023, Booth 1D41 (Zone FDF), from October 24 to 26.
Notably, SINOVAC will debut the Antibody SA55 Injection and Nasal Spray, based on an innovative broad-spectrum neutralizing antibody that advances the treatment and prevention of COVID-19. Recent studies shows these products’ efficacy in neutralizing the omicron variant and its sublineages, including BA.5, BF.7, BQ.1.1, XBB.1.5, BA.2.86 and EG.5.
In addition to these innovative antibody products, SINOVAC will showcase:
· World Health Organization (WHO) prequalified vaccines, including Healive® for hepatitis A; PROVARIX for varicella; and a vaccine for Sabin-strain inactivated polio.
· Highly protective trivalent influenza vaccine, Anflu®, and quadrivalent influenza vaccine, TetrAnflu.
· World-leading enterovirus type 71 vaccine, Inlive®.
· CoronaVac®, one of the most widely administered COVID-19 vaccines globally and the only inactivated COVID-19 vaccine approved for children as young as 6 months old.
"While the WHO has declared an end to the global health emergency caused by COVID-19, the world is still facing the threat of various infectious diseases in 2023," said Ms. Helen Yang, Chief Business Officer of SINOVAC. "As a leading biopharmaceutical product provider in China, SINOVAC remains committed to increasing our investment in R&D, vaccine production and the exploration of cutting-edge biomedical products, including antibodies. It is the right time to introduce our most recent innovations and explore opportunities for international collaboration that aids in our mission to 'Supply Vaccines to Eliminate Human Diseases'."
Discover SINOVAC's comprehensive product portfolio at CPHI Barcelona 2023
Explore SINOVAC's comprehensive portfolio of products and technologies and meet with SINOVAC experts onsite at Booth 1D41 (Zone FDF) or contact Alice Chen via email@example.com to schedule a personalized engagement.
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to pipeline development including but not limited to new technology, new vaccines as well as other biomedical products. We will constantly explore global opportunities of strategic expansion.
For more information, please visit the Company’s website at www.sinovac.com.
Sinovac Biotech Ltd.